Vistagen Therapeutics Inc VTGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
-
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
-
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
-
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
-
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
-
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
-
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
-
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Trading Information
- Previous Close Price
- $0.26
- Day Range
- $0.25–0.26
- 52-Week Range
- $0.20–5.13
- Bid/Ask
- $0.25 / $0.25
- Shares Outstanding
- 41.03M
- Market Cap
- $10.44M
- Volume/Avg
- 347,276 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 41
- Website
- https://www.vistagen.com
Valuation
|
Metric
|
VTGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.26 |
Price/Sales | 7.04 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VTGN
|
|---|---|
Quick Ratio | 3.55 |
Current Ratio | 3.67 |
Interest Coverage | — |
Quick Ratio
VTGN
Profitability
|
Metric
|
VTGN
|
|---|---|
Return on Assets (Normalized) | −95.64% |
Return on Equity (Normalized) | −118.83% |
Return on Invested Capital (Normalized) | −118.79% |
Return on Assets
VTGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^?#&z#B | LOCK|$c#! | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@YWg!z | LOCK|W<CP | $70B | |||
| argenx SE ADR
ARGX
| LOCK|j<$?nmD | LOCK|FZT | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|F$sS%$ | LOCK|!%Y! | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|v!P$r# | LOCK|^z | $36B | |||
| Moderna Inc
MRNA
| LOCK|tWTt@S | LOCK|dF$ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!C!vjP&B | LOCK|K@ZyH | $25B | |||
| Incyte Corp
INCY
| LOCK|$?sbyj | LOCK|f?q | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|h!Rl?<# | LOCK|h!< | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|KL%q&X | LOCK|$@ | $17B |
United States